Phase Forward Reaches 3,000 InForm™ Trials Milestone
WALTHAM, Mass.–(BUSINESS WIRE)–Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its InForm™ electronic data capture (EDC) solution has been utilized in more than 3,000 live or completed clinical trials to date with end users in 112 countries across the globe. Widely adopted by companies of all sizes across multiple industry segments and clinical trial phases, the InForm solution has led the way for the industry’s embrace of EDC technology to help bring therapies to market more efficiently and cost-effectively.
The announcement comes as the company last month unveiled a new generation of InForm, the InForm Global Trial Management (GTM) eClinical solution. InForm GTM addresses the paradigm shift in usability requirements resulting from the maturation of the EDC market whereby longer and more complex trials are managed by more sophisticated and knowledgeable EDC users who require more information.
InForm is a key part of Phase Forward’s suite of solutions offering customers of the world an integrated clinical research suite (ICRS) from study set-up, through analysis and submission. The InForm solution, together with Phase Forward’s Clarix™ interactive response technology (IRT) for randomization and trial supply management; the recently acquired Waban Software platform for the management of all clinical data, analysis and reports; and the Empirica™ safety and pharmacovigilance product sets, offers customers an end-to-end eClinical solution for efficiently managing all their trials.
“We are proud of the leadership role we have played in pioneering the broad adoption of EDC technology to help bring essential treatments to market more quickly,” said Bob Weiler, chairman and CEO, Phase Forward. “We’re thrilled to have reached the 3,000 trials milestone with InForm, and we look forward to continuing to set new standards for eClinical solutions.”
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.
